Clinical Trial Update: Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events [Phase 1]

View source ↗

Summary

A Phase 1 trial testing Tocilizumab-aazg to reduce ischemic vascular events in aneurysmal subarachnoid hemorrhage with delayed cerebral ischemia; recruitment is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aneurysmal Subarachnoid Hemorrhage
• Delayed Cerebral Ischemia

Drugs mentioned

• Tocilizumab-aazg (tocilizumab)

Snippet

Sponsor: University of Florida | Conditions: Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral Ischemia | Phase 1 | Status: RECRUITING